2-Amino-N-{2-[2-(4-butyryl-phenylamino)-oxazol-5-yl]-benzyl}-N-methyl-acetamide | 463941-51-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Amino-N-{2-[2-(4-butyryl-phenylamino)-oxazol-5-yl]-benzyl}-N-methyl-acetamide
• 英文别名: 2-amino-N-[[2-[2-(4-butanoylanilino)-1,3-oxazol-5-yl]phenyl]methyl]-N-methylacetamide
• CAS: 463941-51-7
• 化学式: C₂₃H₂₆N₄O₃
• 分子量: 406.484
• InChiKey: LVGPFXHHCHPINF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
  申请人：——

  公开号：US20020143176A1

  公开（公告）日：2002-10-03

  Compounds having the formula (I), 1 are effective as inhibitors of IMPDH enzyme and/or serine protease Factor VIIa, wherein B is a monocyclic or bicyclic carbocyclic or heterocyclic ring, D is a monocyclic or bicyclic carbocyclic or heterocyclic ring except when A is a heterocyclic ring, then D is a heterocyclic ring system, R is hydrogen or C 1-4 alkyl, and A, R 1 , R 2 and R 4 are as defined in the specification.

  具有(I)式的化合物作为IMPDH酶和/或丝氨酸蛋白酶因子VIIa的抑制剂具有有效性，其中B是单环或双环碳环或杂环，D是单环或双环碳环或杂环，除非A是杂环，那么D就是杂环系统，R是氢或C1-4烷基，A、R1、R2和R4如规范中定义。
• EP1448187A4
  申请人：——

  公开号：EP1448187A4

  公开（公告）日：2005-05-25
• COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  申请人：Bristol-Myers Squibb Company

  公开号：EP1448187A2

  公开（公告）日：2004-08-25
• US6596747B2
  申请人：——

  公开号：US6596747B2

  公开（公告）日：2003-07-22
• [EN] COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME<br/>[FR] COMPOSES DERIVES D'UN NOYAU D'AMINE NUCLEUS ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003047512A2

  公开（公告）日：2003-06-12

  Compounds having the formula (I), are effective as inhibitors of IMPDH enzyme and/or serine protease Factor VIIa, wherein B is a monocyclic or bicyclic carbocyclic or heterocyclic ring, D is a monocyclic or bicyclic carbocyclic or heterocyclic ring except when A is a heterocyclic ring, then D is a heterocyclic ring system, R is hydrogen or C1-4alkyl, and A, R1, R2 and R4 are as defined in the specification.